Payment overview · 2025
General Payments
$227.41
13 reported records · 10 companies
Healthcare provider profile · identity verified
Lee Daniel Logan, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DAYTON, TN · NPI 1336188085
Verified facts
What the public records show
CMS Open Payments records show Lee Daniel Logan, D.O. received $227.41 in general payments during 2025 across 13 reported records.
Novartis Pharmaceuticals Corporation accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.19 | 22.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.80 | 15.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.71 | 9.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.28 | 9.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.99 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.17 | 8.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.99 | 7.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.31 | 6.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.42 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.55 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.41 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.19 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 31 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 700 | 246 |
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 135 |
| Omeprazole | Omeprazole | 327 | 113 |
| Lisinopril | Lisinopril | 263 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 94 |
| Losartan Potassium | Losartan Potassium | 243 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 75 |
| Carvedilol | Carvedilol | 191 | 66 |
| Valsartan | Valsartan | 188 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 61 |
| Gabapentin | Gabapentin | 182 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 62 |
| Alendronate Sodium | Alendronate Sodium | 149 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 144 | 46 |
| Metformin Hcl | Metformin Hcl | 144 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 50 |
| Eliquis | Apixaban | 133 | 32 |
| Potassium Chloride | Potassium Chloride | 126 | 46 |
| Sertraline Hcl | Sertraline Hcl | 119 | 34 |
| Allopurinol | Allopurinol | 117 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 39 |
| Jardiance | Empagliflozin | 113 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 31 |
| Trazodone Hcl | Trazodone Hcl | 108 | 38 |
| Donepezil Hcl | Donepezil Hcl | 105 | 28 |
| Tramadol Hcl | Tramadol Hcl | 101 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 20 |
| Farxiga | Dapagliflozin Propanediol | 97 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 92 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 32 |
| Montelukast Sodium | Montelukast Sodium | 83 | 26 |
| Mounjaro | Tirzepatide | 82 | 26 |
| Meloxicam | Meloxicam | 80 | 28 |
| Famotidine | Famotidine | 78 | 31 |
| Repatha Sureclick | Evolocumab | 77 | 17 |
| Ezetimibe | Ezetimibe | 76 | 25 |
| Simvastatin | Simvastatin | 76 | 26 |
| Furosemide | Furosemide | 75 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 28 |
| Alprazolam | Alprazolam | 68 | 18 |
| Ozempic | Semaglutide | 67 | 18 |
| Synthroid | Levothyroxine Sodium | 67 | 19 |
| Buspirone Hcl | Buspirone Hcl | 66 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 28 |
| Spironolactone | Spironolactone | 61 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 22 |
| Chlorthalidone | Chlorthalidone | 54 | 11 |
| Prednisone | Prednisone | 53 | 40 |
| Metformin Hcl Er | Metformin Hcl | 52 | 19 |
| Pregabalin | Pregabalin | 50 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 11 |
| Trulicity | Dulaglutide | 49 | 14 |
| Glipizide Er | Glipizide | 48 | 16 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 45 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 44 | suppressed |
| Kerendia | Finerenone | 44 | 13 |
| Ramipril | Ramipril | 42 | 15 |
| Novolog Flexpen | Insulin Aspart | 41 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Ibuprofen | Ibuprofen | 39 | 14 |
| Irbesartan | Irbesartan | 39 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | 19 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 14 |
| Celecoxib | Celecoxib | 35 | 15 |
| Benazepril Hcl | Benazepril Hcl | 34 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | 11 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | 14 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Diazepam | Diazepam | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | 11 |
| Estradiol | Estradiol | 25 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 21 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Glipizide | Glipizide | 23 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Fluorouracil | Fluorouracil | 11 | 11 |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.41 · 13 records | Novartis Pharmaceuticals Corporation | ABRYSVO, COMIRNATY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Korlym, LEQVIO, MOUNJARO, OPDIVO, PREVNAR 20, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error